Loading…
Provides sterilization (Sterigenics), radiation-source/testing (Nordion) and lab testing (Nelson Labs) services critical to the medical device and pharma supply chain.
Provides sterilization (Sterigenics), radiation-source/testing (Nordion) and lab testing (Nelson Labs) services critical to the medical device and pharma supply chain.
Sterilisation carries the business: manufacturers pay for each load of devices treated with ethylene oxide gas, gamma rays or electron beams, with recurring orders. Nordion sells Cobalt-60, the radiation source behind gamma sterilisation, supplied from nuclear reactors, and testing is the third line. Lawsuits over ethylene oxide emissions at some US plants are an ongoing legal exposure.
Moat: narrow (regulatory licence, switching costs, installed base). Regulatory-validated sterilization facilities and Cobalt-60 supply access are costly and slow to replicate.
Headquarters: Broadview Heights, Ohio, USA · Founded: 1934 · Employees: 3,000
Size Sotera Health (SHC) is a United States Health Care company (Medical Specialties) with a market value of $4.57B, the 1241st largest of 3,117 United States companies the cockpit tracks. Shares closed at $16.01 on 6 Nov 2026.
Performance Over six months the shares gained 1.5%, against +28.3% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 6.9% over the last twelve months (peer median +4.3%); the operating margin is 36.7% (peer median 13.1%).
Valuation It trades at 15.4× forward earnings against a peer median of 20.2× (3rd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.2 points above its cost of capital (11.5% WACC).
Short interest Short interest is 5.6% of the free float (15 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.23B | $1.16B | $1.10B | $1.05B | $1.00B |
| Revenue growth | — | +6% | +5% | +5% | — |
| Gross profit | $660M | $615M | $540M | $513M | $494M |
| EBITDA | $583M | $555M | $504M | $517M | $477M |
| Net income | $173M | $77.9M | $44.3M | $51.1M | -$234M |
| Free cash flow | $134M | $145M | $45.1M | -$388M | $95.6M |
| Capital expenditure | $196M | $138M | $179M | $215M | $182M |
| Total debt | $2.28B | $2.27B | $2.35B | $2.33B | $2.03B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sotera Health SHC | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% |
| Steris STE | $24.6B | +22% | +8% | 20% | 21.4× | 13.7% |
| Getinge GETI-B.ST | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% |
| Eurofins Scientific ERF.PA | $17.5B | +49% | +3% | 12% | 23.0× | 13.3% |
| Charles River Laboratories CRL | $16.1B | +90% | -1% | 15% | 26.6× | 25.3% |
| Intertek ITRK.L | $12.3B | +12% | +4% | 18% | 22.3× | 14.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SHC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.2% | +7.9% | 5th lowest of 21 |
| 6-month return | +1.5% | +28.3% | 7th lowest of 21 |
| Distance from 52-week high | -19.4% | -15.3% | 9th lowest of 21 |
| Revenue growth (TTM) | +6.9% | +4.3% | 10th highest of 20 |
| Operating margin | 36.7% | 13.1% | highest of 20 |
| Forward P/E | 15.4× | 20.2× | 3rd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 13.7% | 10.6% | 4th most demanding of 16 |
| Growth delivered (Del g) | +7.3% | +8.2% | 7th lowest of 16 |
| Hurdle (Req g minus delivered) | +6.4 pp | +1.7 pp | 4th most demanding of 16 |
| ROIC minus cost of capital | +2.2 pp | +0.8 pp | 9th highest of 19 |
| EV / EBITDA | 11.0× | 14.2× | 4th cheapest of 13 |
| Net debt / EBITDA | 3.2× | 1.1× | 2nd most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% | +7.3% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | 14% | 25.5× | n/a | n/a |
| Intco Medical Technology 300677.SZ | China | $4.40B | -20% | +33% | 20% | 14.7× | -4.7% | -6.4% |
| ICU Medical ICUI | United States | $4.30B | +36% | -9% | 7% | 19.5× | 22.1% | +11.9% |
| Integer ITGR | United States | $4.30B | +44% | 0% | 9% | 18.8× | 19.6% | +11.5% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.26B | -1% | -1% | 13% | 20.4× | 5.1% | +3.4% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 13% | 19.9× | 11.5% | +8.2% |
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% | +6.3% |
| CareDx CDNA | United States | $4.13B | +260% | +39% | 1% | 53.2× | n/a | n/a |
| Fielmann FIE.DE | Germany | $4.12B | +3% | +3% | 14% | 17.8× | -5.3% | +11.3% |
| Tecan TECN.SW | Switzerland | $4.05B | +91% | -4% | 1% | 40.1× | 46.9% | +3.8% |
| Envista NVST | United States | $4.04B | +4% | +12% | 11% | 15.6× | 6.8% | +7.1% |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |
| Pulse Biosciences PLSE | United States | $3.87B | +179% | n/a | -7,008% | n/a | n/a | n/a |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| Stevanato STVN | United States | $3.70B | -26% | +12% | 18% | 19.3× | 10.6% | +12.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.67B | +31% | +4% | 15% | 22.1× | 11.7% | +11.0% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -3% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Andon Health 002432.SZ | China | $3.60B | -29% | -30% | -26% | 15.0× | -7.7% | -7.4% |
| iRay Technology 688301.SS | China | $3.54B | -8% | +58% | 24% | 27.5× | n/a | n/a |